Renalytix Announces Publication Of Real World Evidence After 12 Months Of Follow-up, Demonstrate KidneyIntelX In Vitro Prognostic Testing Was Associated With Clinical Actions Leading To Significant Slowing Of Chronic Kidney Disease Progression
Portfolio Pulse from Benzinga Newsdesk
Renalytix has announced that a real-world evidence study published after 12 months of follow-up shows that its KidneyIntelX in vitro prognostic testing is associated with clinical actions that significantly slow the progression of chronic kidney disease (CKD).
January 10, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The publication of positive real-world evidence for Renalytix's KidneyIntelX test could lead to increased adoption and revenue, potentially boosting RNLX's stock price in the short term.
The publication of a study demonstrating the effectiveness of Renalytix's KidneyIntelX test in slowing CKD progression is likely to be viewed positively by investors and could lead to increased demand for the test. This, in turn, may result in higher revenues for the company and a positive impact on the stock price. The confidence in this analysis is high due to the direct correlation between product efficacy and company performance, especially in the healthcare sector.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100